Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;15(9):e007960.
doi: 10.1161/CIRCEP.121.007960. Epub 2022 Sep 8.

Sinus Tachycardia: a Multidisciplinary Expert Focused Review

Affiliations
Review

Sinus Tachycardia: a Multidisciplinary Expert Focused Review

Kenneth A Mayuga et al. Circ Arrhythm Electrophysiol. 2022 Sep.

Abstract

Sinus tachycardia (ST) is ubiquitous, but its presence outside of normal physiological triggers in otherwise healthy individuals remains a commonly encountered phenomenon in medical practice. In many cases, ST can be readily explained by a current medical condition that precipitates an increase in the sinus rate, but ST at rest without physiological triggers may also represent a spectrum of normal. In other cases, ST may not have an easily explainable cause but may represent serious underlying pathology and can be associated with intolerable symptoms. The classification of ST, consideration of possible etiologies, as well as the decisions of when and how to intervene can be difficult. ST can be classified as secondary to a specific, usually treatable, medical condition (eg, pulmonary embolism, anemia, infection, or hyperthyroidism) or be related to several incompletely defined conditions (eg, inappropriate ST, postural tachycardia syndrome, mast cell disorder, or post-COVID syndrome). While cardiologists and cardiac electrophysiologists often evaluate patients with symptoms associated with persistent or paroxysmal ST, an optimal approach remains uncertain. Due to the many possible conditions associated with ST, and an overlap in medical specialists who see these patients, the inclusion of experts in different fields is essential for a more comprehensive understanding. This article is unique in that it was composed by international experts in Neurology, Psychology, Autonomic Medicine, Allergy and Immunology, Exercise Physiology, Pulmonology and Critical Care Medicine, Endocrinology, Cardiology, and Cardiac Electrophysiology in the hope that it will facilitate a more complete understanding and thereby result in the better care of patients with ST.

Keywords: autonomic dysfunction; hyperthyroidism; inappropriate sinus tachycardia; post-COVID syndrome; postural orthostatic tachycardia syndrome; sinus tachycardia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Evaluation of sinus tachycardia.
AAbs, autoantibodies; ABG, arterial blood gas; ABPM, ambulatory blood pressure monitoring; AF, atrial fibrillation; AFL, atrial flutter; AVNRT, atrioventricular node re-entry tachycardia; AVRT, atrioventricular re-entry tachycardia; BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise testing; CRP, C-reactive protein; EAT, ectopic atrial tachycardia; hCG, human chorionic gonadotropin; ILD, interstitial lung disease; IST, inappropriate sinus tachycardia; MCAS, mast cell activation syndrome; LV, left ventricle; PCT, procalcitonin; PFTs, pulmonary function tests; PGD2, prostaglandin D2; POTS, postural orthostatic tachycardia syndrome; RV, right ventricle; SNRT, sinus node re-entry tachycardia; ST, sinus tachycardia; TSH, thyroid-stimulating hormone; VHD, valvular heart disease; WBC, white blood cells; 6MWT, 6-minute walking test.
Figure 2.
Figure 2.. Autonomic control of the sinoatrial node activity and modulators of autonomic inputs.
Created with Biorender.com
Figure 3.
Figure 3.. Classification of Sinus Tachycardia.
Created with Biorender.com
Figure 4.
Figure 4.. Work-up of sinus tachycardia following COVID-19.

References

    1. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol. 1993;55:455–472. doi: 10.1146/annurev.ph.55.030193.002323 - DOI - PubMed
    1. Aune D, Sen A, o’Hartaigh B, Janszky I, Romundstad PR, Tonstad S, Vatten LJ. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - A systematic review and dose-response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27:504–517. doi: 10.1016/j.numecd.2017.04.004 - DOI - PubMed
    1. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30:1104–1106. doi: 10.1016/s0735-1097(97)00246-5 - DOI - PubMed
    1. Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Ther. 2001;6:313–331. doi: 10.1177/107424840100600401 - DOI - PubMed
    1. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823–830. doi: 10.1016/j.jacc.2007.04.079 - DOI - PubMed